



EMERSE: electronic medical record search engine

Panel – The National Cancer Institute's Informatics Technology for Cancer Research Program: Building A Community of Practice in Cancer Informatics

S34

David Hanauer, MD, MS

University of Michigan

Twitter: @davidhanauer2

#AMIA2019



Disclosure



I and my spouse/partner have no relevant relationships with commercial interests to disclose.

What is EMERSE?



Self-service search tool for the medical record free text notes

→ the 80% not captured in structured data

Helps people abstract the phenotype, for non-coded data

→ e.g., metastatic ductal vs. metastatic lobular breast cancer


Easy to use for typical research staff

→ finds cohorts or highlights notes within a cohort

Scales well

Secure and regulatory compliant (audit logs, etc)

Simple—it's not full NLP, but often NLP isn't needed: “augmented intelligence”



Patients

All (2,351,932)

Dates

All Dates: 01/01/1900 through 05/18/2018

Terms

"Epithelioid hemangioendothelioma"

User: hanauerEMERSE

116 patients matched the search criteria

100 top-ranked document summaries are shown.
To review these patients in more detail, move them to a Temporary Patient List and then run the search again.

Move patients to Temporary Patient List

Revise Terms

Sort charts by Demographics

Sort charts by Frequency

Gender

Female

75

Male

40

Unknown

Summary

...suggestive of epithelioid hemangioendothelioma. See COMMENT...

...includes epithelioid hemangioendothelioma, poorly differentiated...

...considerations, epithelioid hemangioendothelioma is our primary...

...History of epithelioid hemangioendothelioma. About 30...

...with known epithelioid hemangioendothelioma. This scan...

...history of epithelioid hemangioendothelioma. Please note...

...HISTORY: Epithelioid hemangioendothelioma. COMPARISON:...

...diagnosis of epithelioid hemangioendothelioma. There is...

...diagnosis of epithelioid hemangioendothelioma...

...COMPLAINT: Epithelioid hemangioendothelioma of the liver...

...angiosarcoma versus epithelioid hemangioendothelioma. He was evaluated...

...consistent with epithelioid hemangioendothelioma. The latest...

...diagnosed epithelioid hemangioendothelioma of the liver...

...liver biopsy) Epithelioid hemangioendothelioma. CD31 highlights...

...man with epithelioid hemangioendothelioma of the liver...

...liver. Epithelioid hemangioendothelioma in the liver...

... Since epithelioid hemangioendothelioma is indolent...

...hepatic epithelioid hemangioendothelioma and history...

...needle biopsy: Epithelioid hemangioendothelioma. ...

...results/plan for her epithelioid hemangioendothelioma. Labs from...

...metastatic epithelioid hemangioendothelioma. CTs have...

...): Epithelioid hemangioendothelioma. Immunohistochemical...

...): Epithelioid hemangioendothelioma. Immunohistochemical...

...of case: Epithelioid hemangioendothelioma. GROSS:...

...): Epithelioid hemangioendothelioma. COMMENT:...

...metastatic epithelioid hemangioendothelioma with enlarged...


...Metastatic epithelioid hemangioendothelioma. ...

...consistent with epithelioid hemangioendothelioma seen in subsequent...

... (...): Epithelioid hemangioendothelioma (CD31, factor...

AMIA 2019 Annual Symposium | amia.org

4



Patients

Demo List (new) (12 Patients)

User: emerse

EMERSE

Dates

All Dates: 02/15/2008 through 09/28/2011

Terms

cd20

cd5

cd34

cd10

cd3

cd45

"marginal zone lymphoma"

"BCL 2"

BEXXAR

rituximab

cytoxin

"R CHOP"

anthracycline

"autologous stem cell transplant"

"diffuse large cell lymphoma"

"salvage therapy"

More...

Overview

Summaries

Patel, Joshua

1000000047

Comment

Tag

Patient 2 of 12

Document 4 of 10

Page Top

Page Bottom

Print

ADMITTING DIAGNOSIS: Relapsed **Diffuse large cell lymphoma**

TRANSPLANT TYPE: Autologous

PROTOCOL: CTN 0401 (**Bexxar** - BEAM)

TRANSPLANT DATE: **DATE

VIRAL TITERS: CMV positive, HSV positive, VZV positive

HISTORY OF PRESENT ILLNESS: Mr. **NAME is a **AGE year old male who is being admitted for an **autologous stem cell transplant** per BMT CTN ; randomized to **Bexxar**-BEAM therapy. Mr. **NAME is currently admitted to undergo the BEAM portion of his conditioning regimen. **Autologous stem cell transplant** is scheduled for **DATE.

PAST MEDICAL HISTORY: The patient presented in **DATE, with proptosis of the right eye and sinus congestion. A CT scan at that time revealed a 3.4 cm x 5.8 cm right orbital mass, and 6.7 cm x 3.7 cm right maxillary mass. The patient had developed significant exophthalmos of the right eye with visual changes along with coexistent bilateral cervical adenopathy. A biopsy of the mass was obtained on **DATE, initially consistent with a **CD20** positive, **CD45** positive, **BCL-2** positive, **marginal zone lymphoma**. The patient was subsequently treated with 5 cycles of **R-CHOP** between **DATE, and **DATE.

A second-look surgery performed on **DATE, of the right ethmoid and right maxillary sinus mass revealed that the lesion had transformed to a **diffuse large cell lymphoma**, again **CD20** positive, **CD45** positive, **BCL-2** positive. The patient subsequently received 4 additional cycles of **R-CHOP** between **DATE, through **DATED, YYYY>. He has now received a total **anthracycline** dose of 240 mg/sq. m. A CT scan obtained at the end of induction therapy revealed a CR status. No XRT was given.

In **DATE, the patient developed recurrent nasal congestion with the lacrimal duct obstruction. A CT scan on **DATED, YYYY>, revealed a new left maxillary mass, 4.5 cm in maximal diameter. The mass extended from the midline of the oropharynx laterally to the point of the lateral pterygoid plate on the left side. Thus, the patient recurred contralateral to the initial side of disease. There was no other adenopathy in the chest or abdomen on screen at that time. The patient started **salvage therapy** with **RICE** **DATE. He has received 2 cycles of **RICE** to date, the 2nd cycle given **DATE. He enrolled on CTN in **DATE, receiving **rituximab** , and **cytoxin** 4 gm/m2 . He underwent autologous stem cell collection **DATED>--**DATE, with 4.4 x 10(6) **CD34** cells/kg collected.

In preparation for his **Bexxar** dosimetry on **DATE, the patient

PatientsAll (2,351,932)

DatesAll Dates: 01/01/1900 through 05/18/2018

Termsemesis

Quick Terms

Term Bundles

Advanced Terms

Name/Description

Manage Terms

View Terms

Sharing

Clear/Delete

The current settings will enable you to search through **All Patients**. Terms with different colors will be searched using the AND operator. Patients identified will be those that have at least one document. With a **Quick Terms** search, EMERSE assigns the colors to the terms.

The current screen looks similar to a **Term Bundle** screen, but be able to adjust the colors of the terms yourself.

For more control over the colors assigned to terms, use a **Term Bundle** screen. For more control over your search criteria, such as combining Boolean operators, use the **Advanced Terms** screen.

Search Options

Terms to include

Click on the term to edit

emesis

Synonyms

Click individual terms to highlight or de-highlight

Synonyms (119)

barfbarfedarferbarfingbarfsblowing chunkschunderchunderedchunderingchundersdry heavedry heaveddry heavesdry heavingemesesemeticemeticsemetogenicemetogenicityheaveheavedheavesheavinghurlhurledhurlerhurlinghurlsdryheavinginducedvomitinginducesvomitinginducingvomitingN & V N and V N&V N/V nausea nausea & vomitingnausea / vomitingnausea and vomitingnausea or vomitingnausea vomitingnausea/vomitingnauseate nauseatednauseatesnauseatingnauseousnauseousnessNBNB emesisnon-bloody, non-bilious emesisnon-bloody, nonbilious emesisnonbloody, non-bilious emesisnonbloody, nonbilious emesisNVpost-anesthesia emesispost-anesthesia vomitingpost-anesthetic emesispost-anesthetic vomitingpost-tussive emesispostanesthesia emesispostanesthesia vomitingpostanesthetic emesispostanesthetic vomitingposttussive emispukepukedpukerpukespukingpurgepurgedpurgerpurgespurgingqueasinessqueasyralphralphsregurgitate regurgitatedregurgitatesregurgitatingretchretchedretchesretchingreverse peristalsisthrew it all upthrew it upthrew upthrow it all upthrow it upthrow upthrowing chunksthrrowing it all upthrowing it upthrowing upthrows it all upthrows it upthrows uptossing cookiesup-chuckup-chuckedup-chuckingup-chucksupchuckupchuckedupchuckingupchucksvomitvomitedvomitervomitersvomitingvomitivevomitoryvomitsvomitus

Spelling Alternatives (9)

emeisemeisisemeissemisemisismetictmeticsnause and vomittingqueaziness

Highlight All

De-Highlight All

Add Highlighted Terms

AMIA 2019 Annual Symposium | amia.org

7

Goals of the EMERSE project



Develop new functionality for the software

- Improved query suggestion
- Networking across sites (“SHRINE-like”)

Create the infrastructure for dissemination of an enterprise-level search tool

- Build the community
- Documentation for end-users and implementers
- Training materials

Engaging with users



Two kinds of “users”:


1. System implementers (who have many local challenges)

- engagement with ITCR support
- building the community

2. Standard users

- engagement through training sessions (group and 1:1)
- usability interviews
- users often approach us with requests for features

EMERSE Sites



What ITCR support means



The ability to scale up from a local effort to a national one

The ability to build the infrastructure needed for broad dissemination

Protected time to engage with other sites, provide demos, etc

Protected time to engage with users

Developer effort

A peer/mentoring network of ITCR software developers

Developing software in academic setting



Pros:

understand the challenging environment in which the software must exist

- access to the data
- regulatory concerns
- prioritization of projects with limited resources
- security

Cons:

shifting between local work vs national focus based on dual funding streams

other academic demands (teaching, publishing, etc)

security

Security



Quickly becoming a major concern and priority of medical centers


The days of installing any software in the clinical environment are gone

Rigorous security reviews are required before allowed to operate

Adds a major amount of time/effort/expense

Can never fall behind – otherwise, the plug gets pulled

Reviews designed for vendor software, doesn't work as well for open source



Security



cybersecurity
technical design

risk assessment

information system
contingency plan

stakeholders
document

firewall change
request

penetration
testing

vulnerability
scans

interconnect
document

shared responsibility
agreement

software security
code review

vendor security
assessment

**This is a
lot of work!**

Acknowledgements



ITCR (NIH NCI): U24CA204863

MICHR (NIH CTSA): UL1TR000433 and UL1TR002240

U of Michigan Rogel Cancer Center (NIH NCI): P30CA046592

EMERSE Development Team: James Law, Ritu Khanna, Kellen McClain, Raghu Tadi, Rachael Hodder, Doran Steele, Long Zhang

EMERSE Partners: Jill Barnholtz-Sloan, Mark Beno, James Champion, Bront Davis, Guilherme Del Fiol, Eric Durbin, Oksana Gologorskaya, Daniel Harris, Brett Harnett, Kensaku Kawamoto, Benjamin May, Eric Meeks, Emily Pfaff, Janie Weiss, Kai Zheng

Learn more about EMERSE



hanauer@umich.edu

project-emerse.org